Saturday 17 October 2026 Export MIRA’s income statement to Excel — free account

MIRA Pharmaceuticals, Inc.

MIRA Healthcare Drug Manufacturers General

In the quarter to June 2026, EPS grew 66.7% and free cash flow fell 50.8%, each against the same quarter a year earlier.

0.63 0.03 −4.55%

Follow MIRA

Alert me

Market cap: $27.7M
P/E: 0.0×
Fwd P/E: —
Dividend yield: —
F-score: n/a
Altman Z: n/a
Beneish M: n/a
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 7.93%

Capital & Financial Ratios $m

Market Cap 27.65

Revenue —

Net Income (9.48)

Free Cash Flow (4.64)

Net Debt (8.11)

Current Ratio 200.19

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E —

P/S ratio 0.00

P/B ratio 3.24

Past 5Y EPS Growth —

This Y EPS Growth (122.86%)

Next Y EPS Growth 84.62%

Next Y revenue growth —

Next 5Y EPS Growth 32.70%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

P/B against its own 10 years 12.42%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	5	3	11	8
Receivables	0	—	—	—
Inventory	—	—	—	—
Other	—	—	—	—
	5	3	11	8

	2023	2024	2025	Q'26
Payables	1	1	0	0
ST’ Debt	—	—	—	—
Other	—	—	—	—
	1	1	1	0

Compound Annual Growth %

	10y	5y	3y
Sales	—	—	—
Cash Flow	—	0.00%	0.00%
Earnings	—	0.00%	0.00%
Book Value	—	0.00%	0.00%

Revenue $m

	Year

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(1)	(1)	—	—	—
’25	(2)	(1)	(1)	(1)	(5)
’24	(1)	(1)	(2)	(2)	(6)
’23	(1)	(1)	(2)	(1)	(5)
’22	—	(3)	(1)	(1)	(6)
’21	—	—	—	—	(1)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(1)	(1)	—	—	—
’25	(2)	(1)	(1)	(1)	(5)
’24	(1)	(1)	(2)	(2)	(6)
’23	(1)	(1)	(2)	(1)	(5)
’22	—	(3)	(1)	(1)	(6)
’21	—	—	—	—	(1)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.03)	(0.03)	—	—	—
’25	(0.11)	(0.09)	(1.18)	(0.18)	(1.35)
’24	(0.12)	(0.11)	(0.14)	(0.15)	(0.51)
’23	(0.08)	(0.10)	(0.26)	(0.43)	(0.86)
’22	—	(0.19)	(0.14)	—	(0.40)
’21	—	—	—	—	(0.15)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	—	—	—	—	—	—	0.92	0.51	0.73	Analyst estimates 2026–2028 Powerpack
	High	—	—	—	—	—	—	—	7.98	5.01	2.45
People
People	Employees	—	—	—	—	—	—	6	3	5	2
	Revenue/emp, $m	—	—	—	—	—	—	0.00	0.00	0.00	0.00
Income, $m
Income, $m	Revenue	—	—	—	—	—	—	—	—	—	—
	Gross margin, %	—	—	—	—	—	—	—	—	—	—
	EBT	—	—	—	—	0	(2)	(7)	(12)	(8)	(10)
	EBT margin, %	—	—	—	—	0.00	0.00	0.00	0.00	0.00	0.00
	Net income	—	—	—	—	0	(2)	(7)	(12)	(8)	(10)
	Depreciation	—	—	—	—	—	—	—	—	—	—
Per share, $
Per share, $	Revenue	—	—	—	—	0.00	0.00	0.00	0.00	0.00	0.00
	Earnings	—	—	—	—	0.00	(0.15)	(0.40)	(0.86)	(0.51)	(1.35)
	Cash flow	—	—	—	—	0.00	(0.09)	(0.32)	(0.33)	(0.36)	(0.20)
	Capex	—	—	—	—	0.00	0.00	0.00	0.00	0.00	0.00
	Free cash flow	—	—	—	—	0.00	(0.09)	(0.32)	(0.33)	(0.36)	(0.20)
	Book value	—	—	—	—	0.00	0.15	(0.03)	0.31	0.14	0.44
	Shares, m	—	—	—	—	15	15	18	14	15	24
Valuation, ×
Valuation, ×	P/E	—	—	—	—	—	—	—	—	—	—
	P/S	—	—	—	—	—	—	—	—	—	—
	P/B	—	—	—	—	—	—	—	—	—	—
	EV/Sales	—	—	—	—	—	—	—	—	—	—
	EV/FCF	—	—	—	—	—	—	—	—	—	—
Cash, $m
Cash, $m	Operating cash flow	—	—	—	—	0	(1)	(6)	(5)	(6)	(5)
	Capex	—	—	—	—	—	—	—	—	—	—
	Free cash flow	—	—	—	—	0	(1)	(6)	(5)	(6)	(5)
Balance, $m
Balance, $m	Working capital	—	—	—	—	0	2	(1)	4	2	10
	Total debt	—	—	—	—	0	0	0	—	—	—
	Net debt	—	—	—	—	0	(3)	0	(5)	(3)	(11)
	Shareholders’ equity	—	—	—	—	0	2	(1)	4	2	10
Returns, %
Returns, %	ROA	—	—	—	—	0.00	(128.65)	(335.04)	(413.86)	(199.93)	(456.59)
	ROIC	—	—	—	—	0.00	0.00	0.00	0.00	0.00	0.00
	ROE	—	—	—	—	0.00	(197.93)	(847.73)	(634.30)	(238.90)	(508.28)

Negative figures in brackets.

All 10 years →

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
SNY Sanofi	$96.0B	21.3×	—	+17.35% (above 0%: growing)	−90.76% (below 0%: shrinking)	−45.06% (below 0%: shrinking)	75.47%	17.48%	Compare
BIIB Biogen Inc.	$34.8B	41.0×	31.5×	+3.42% (above 0%: growing)	−84.76% (below 0%: shrinking)	+103.28% (above 0%: growing)	71.60%	5.52%	Compare
OGN Organon & Co.	$3.6B	17.4×	5.2×	−2.26% (below 0%: shrinking)	−26.79% (below 0%: shrinking)	−82.97% (below 0%: shrinking)	54.36%	20.67%	Compare
GRFS Grifols, S.A.	$2.0B	8.5×	—	+5.76% (above 0%: growing)	+466.92% (above 0%: growing)	+300.52% (above 0%: growing)	36.47%	14.76%	Compare
AMRN Amarin Corporation PLC	$244.4M	— (loss-making)	— (loss-making)	−41.97% (below 0%: shrinking)	n/m	−60.23% (below 0%: shrinking)	35.51%	(28.45%)	Compare
NSRX Nasus Pharma Ltd.	$37.1M	—	—	—	—	−486.98% (below 0%: shrinking)	—	—	Compare
MIRA MIRA Pharmaceuticals, Inc.	$27.7M	— (loss-making)	—	—	n/m	−50.76% (below 0%: shrinking)	—	0.00%
SCLX Scilex Holding Company	$19.8M	— (loss-making)	— (loss-making)	−22.78% (below 0%: shrinking)	n/m	−203.76% (below 0%: shrinking)	51.88%	(385.02%)	Compare
MDCX Medicus Pharma Ltd	$6.3M	— (loss-making)	—	—	n/m	−27.70% (below 0%: shrinking)	—	0.00%	Compare
Median of peers	$1.1B	19.3×	—	+0.58%	−55.77%	−52.64%	53.12%	5.52%

All 21 Drug Manufacturers General stocks →

MIRA Pharmaceuticals, Inc. (MIRA) key facts

MIRA Pharmaceuticals, Inc. (MIRA) is a Drug Manufacturers General company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, MIRA traded at $0.63, a market capitalization of $27.7 million.
Return on equity was −508.3% and debt-to-equity 0.00.

Source: company filings (standardised) and stockrow calculations.